E S Dellon1,2, L L Higgins1, R Beitia1, S Rusin3, J T Woosley3, R Veerappan4, S R Selitsky5, J S Parker5, R M Genta4,6, R H Lash4, R Aranda7, R J Peach7, M Grimm7. 1. Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 2. Division of Gastroenterology and Hepatology, Department of Medicine, Center for Gastrointestinal Biology and Disease, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 3. Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 4. Miraca Life Sciences Research Institute, Irving, TX, USA. 5. Department of Genetics, University of Chapel Hill, Chapel Hill, NC, USA. 6. Dallas Veterans Affairs Medical Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. 7. Receptos, San Diego, CA, USA.
Abstract
BACKGROUND: Periostin is highly expressed in eosinophilic oesophagitis (EoE), but has not been extensively studied as a non-invasive biomarker. AIM: To assess whether serum periostin distinguished EoE from controls at baseline, had utility for monitoring treatment response, or was associated with IL-13 levels. METHODS: This was a sub-analysis of a prospective cohort study of adults undergoing out-patient upper endoscopy. Incident cases of EoE were diagnosed per consensus guidelines. Controls were subjects with either GERD or dysphagia without EoE. EoE patients were treated with swallowed/topical steroids and had repeat endoscopy/biopsy. Serum periostin levels for cases and controls were compared at baseline, and pre/post-treatment levels were compared for cases. Serum IL-13 and tissue expression of periostin were also assessed. RESULTS: A total of 61 incident EoE cases and 87 controls were analysed. Despite a marked increase in tissue periostin expression in cases, the median baseline serum periostin level was only slightly higher in cases than controls (22.1 ng/mL vs. 20.7; P = 0.04); there was no change in post-treatment levels. There was also no difference in serum periostin for cases by histologic response or atopic status. There was a strong trend towards higher serum IL-13 levels in cases in the highest periostin quartile (57.1 pg/mL vs. 2.6; P = 0.07). CONCLUSIONS: Serum periostin levels were similar in cases and controls, and there were no changes post-treatment. Given elevated IL-13 levels in the EoE patients with the highest periostin levels, future studies could explore periostin as a biomarker in EoE, perhaps in the setting of anti-IL-13 therapy.
BACKGROUND:Periostin is highly expressed in eosinophilic oesophagitis (EoE), but has not been extensively studied as a non-invasive biomarker. AIM: To assess whether serum periostin distinguished EoE from controls at baseline, had utility for monitoring treatment response, or was associated with IL-13 levels. METHODS: This was a sub-analysis of a prospective cohort study of adults undergoing out-patient upper endoscopy. Incident cases of EoE were diagnosed per consensus guidelines. Controls were subjects with either GERD or dysphagia without EoE. EoE patients were treated with swallowed/topical steroids and had repeat endoscopy/biopsy. Serum periostin levels for cases and controls were compared at baseline, and pre/post-treatment levels were compared for cases. Serum IL-13 and tissue expression of periostin were also assessed. RESULTS: A total of 61 incident EoE cases and 87 controls were analysed. Despite a marked increase in tissue periostin expression in cases, the median baseline serum periostin level was only slightly higher in cases than controls (22.1 ng/mL vs. 20.7; P = 0.04); there was no change in post-treatment levels. There was also no difference in serum periostin for cases by histologic response or atopic status. There was a strong trend towards higher serum IL-13 levels in cases in the highest periostin quartile (57.1 pg/mL vs. 2.6; P = 0.07). CONCLUSIONS: Serum periostin levels were similar in cases and controls, and there were no changes post-treatment. Given elevated IL-13 levels in the EoE patients with the highest periostin levels, future studies could explore periostin as a biomarker in EoE, perhaps in the setting of anti-IL-13 therapy.
Authors: Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves Journal: J Allergy Clin Immunol Date: 2011-04-07 Impact factor: 10.793
Authors: Bram D van Rhijn; Joanne Verheij; Marius A van den Bergh Weerman; Caroline Verseijden; René M J G J van den Wijngaard; Wouter J de Jonge; Andreas J P M Smout; Albert J Bredenoord Journal: Am J Gastroenterol Date: 2015-08-25 Impact factor: 10.864
Authors: Evan S Dellon; Ademola Aderoju; John T Woosley; Robert S Sandler; Nicholas J Shaheen Journal: Am J Gastroenterol Date: 2007-07-07 Impact factor: 10.864
Authors: Marc E Rothenberg; Ting Wen; Allison Greenberg; Oral Alpan; Benjamin Enav; Ikuo Hirano; Kari Nadeau; Sergio Kaiser; Thomas Peters; Antonio Perez; Ieuan Jones; Jonathan P Arm; Robert M Strieter; Ronald Sabo; Kulasiri A Gunawardena Journal: J Allergy Clin Immunol Date: 2014-09-13 Impact factor: 10.793
Authors: Ekaterina Safroneeva; Alex Straumann; Michael Coslovsky; Marcel Zwahlen; Claudia E Kuehni; Radoslaw Panczak; Nadine A Haas; Jeffrey A Alexander; Evan S Dellon; Nirmala Gonsalves; Ikuo Hirano; John Leung; Christian Bussmann; Margaret H Collins; Robert O Newbury; Giovanni De Petris; Thomas C Smyrk; John T Woosley; Pu Yan; Guang-Yu Yang; Yvonne Romero; David A Katzka; Glenn T Furuta; Sandeep K Gupta; Seema S Aceves; Mirna Chehade; Jonathan M Spergel; Alain M Schoepfer Journal: Gastroenterology Date: 2015-11-14 Impact factor: 22.682
Authors: Nicola A Hanania; Michael Noonan; Jonathan Corren; Phillip Korenblat; Yanan Zheng; Saloumeh K Fischer; Melissa Cheu; Wendy S Putnam; Elaine Murray; Heleen Scheerens; Cecile T J Holweg; Romeo Maciuca; Sarah Gray; Ramona Doyle; Dana McClintock; Julie Olsson; John G Matthews; Karl Yen Journal: Thorax Date: 2015-05-22 Impact factor: 9.139
Authors: Swathi Eluri; Athidi G Earasi; Susan E Moist; Evan S Dellon; Nicholas J Shaheen Journal: Clin Gastroenterol Hepatol Date: 2019-05-08 Impact factor: 11.382
Authors: Brittany T Hines; Matthew A Rank; Benjamin L Wright; Lisa A Marks; John B Hagan; Alex Straumann; Matthew Greenhawt; Evan S Dellon Journal: Ann Allergy Asthma Immunol Date: 2018-05-16 Impact factor: 6.347
Authors: B L Wright; S I Ochkur; N S Olson; K P Shim; E A Jacobsen; M A Rank; E S Dellon; J J Lee Journal: Dis Esophagus Date: 2018-02-01 Impact factor: 3.429